Data Expected in Q4 2025 from Study Evaluating the First Potential Therapy for Post-Viral Hyposmia
DELRAY BEACH, Fla., April 10, 2025 /PRNewswire/ — Cyrano Therapeutics, Inc., a clinical-stage regenerative medicine company pioneering the development of treatments for smell loss, today announced that it has completed enrollment in the Phase 2 FLAVOR trial, a randomized, double-blinded, placebo-controlled, multi-dose clinical study evaluating CYR-064, its novel soft-mist nasal spray product candidate, for the treatment of post-viral hyposmia (smell loss). Data from the trial is expected in the fourth quarter of 2025.
The FLAVOR trial enrolled 150 patients across 14 clinical sites in the United States to assess the safety, tolerability, and efficacy of CYR-064 for the treatment for post-viral hyposmia compared to placebo over a six-month period. Post-viral hyposmia, a chronic sensory condition with no FDA-approved treatment, is an increasingly prevalent issue affecting more than 60 million people between the US, Europe and Japan, and millions more worldwide.
“Completion of enrollment in our FLAVOR trial is a significant milestone in our mission to develop the first potential pharmaceutical treatment for post-viral smell loss,” said Rick Geoffrion, President and CEO of Cyrano Therapeutics, Inc. “We are deeply grateful to the patients and investigators who have contributed to this critical research, and we look forward to analyzing the data, which will be instrumental in guiding the next phase of CYR-064’s development.”